Cystamine

Cystamine

SCHEMBL445194

NC(=O)O.NCCSSCCN

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
THPO P40225 1/20 0.62
MAPT P10636 4/20 0.59
TDP1 Q9NUW8 3/20 0.59
EHMT2 Q96KQ7 1/20 0.59
ACHE P22303 1/20 0.44
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 2/20 0.39
NOS1 P29475 1/20 0.39
LMNA P02545 3/20 0.38
CYP3A4 P08684 1/20 0.38
APEX1 P27695 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GLRA1 P23415 1/20 0.37
SLC6A9 P48067 1/20 0.37
OR51E2 Q9H255 1/20 0.37
THRB P10828 2/20 0.35
BLM P54132 2/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cystamine SCHEMBL31646100 1.00 TSHR (0.62) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL9417963 0.90 TSHR (0.67) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL1133055 0.85 TSHR (0.59) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL9187228 0.85 TSHR (0.59) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL8660518 0.85 TSHR (0.59) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL28779847 0.82 TSHR (0.63) TSHRTHPOMAPTTDP1EHMT2
SCHEMBL142602 0.82 TSHR (0.72) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL28125490 0.82 TSHR (0.48) TSHRTHPOMAPTTDP1EHMT2
Cystamine SCHEMBL9753048 0.80 TDP1 (0.58) TSHRTHPOMAPTTDP1EHMT2
SCHEMBL5458497 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210154308-A1 POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY NOVARTIS AG (CH) 2021-05-27 US disclosed
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2020-02-13 US disclosed
EP-3566719-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES Cerulean Pharma Inc. (US) 2019-11-13 EP disclosed
US-20180193486-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. 2018-07-12 US disclosed
US-20180008719-A1 POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2018-01-11 US disclosed
US-20170368194-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC (US) 2017-12-28 US disclosed
US-9610360-B2 Polymer drug conjugates with tether groups for controlled drug delivery CERULIEAN PHARMA INC. (US) 2017-04-04 US disclosed
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-03 US disclosed
US-20150005230-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2015-01-01 US disclosed
EP-2809686-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY Cerulean Pharma Inc. (US) 2014-12-10 EP disclosed
WO-2013025490-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES CERULEAN PHARMA INC. (US) 2013-02-21 WO disclosed
US-20120064107-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE CERULEAN PHARMA INC. (US) 2012-03-15 US disclosed
WO-2011146638-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES CERULEAN PHARMA INC. (US) 2011-11-24 WO disclosed
US-20110282047-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. (US) 2011-11-17 US disclosed
EP-2107910-A2 POLYMER-DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY Insert Therapeutics, Inc. (US) 2009-10-14 EP disclosed
WO-2008076333-A9 POLYMER-DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY INSERT THERAPEUTICS INC (US) 2009-01-29 WO disclosed
US-20080176958-A1 Cyclodextrin-based polymers for therapeutics delivery INSERT THERAPEUTICS, INC. (US) 2008-07-24 US disclosed
WO-2008076333-A2 POLYMER-DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY INSERT THERAPEUTICS, INC. (US) 2008-06-26 WO disclosed
EP-0602912-B1 Compositions and agents for vulcanishing rubber ROBINSON BROS LTD (GB) 1998-06-10 EP disclosed
EP-0602912-A1 Compositions and agents for vulcanishing rubber ROBINSON BROTHERS LIMITED (GB) 1994-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210154308-A1 POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY CD44, MSN, ABCB1 TSHR 2821/4885THPO 3072/4885MAPT 246/4885
US-20170368194-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC TSHR 3583/4885THPO 837/4885MAPT 453/4885
US-20180193486-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE PHOSPHO1, SGMS1, SGMS2 TSHR 2636/4885THPO 134/4885MAPT 2965/4885
US-20180008719-A1 POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY CD44, MSN, ABCB1 TSHR 2821/4885THPO 3072/4885MAPT 246/4885
US-20080176958-A1 Cyclodextrin-based polymers for therapeutics delivery CD47, SDCBP, BST2 TSHR 3297/4885THPO 1649/4885MAPT 342/4885
US-20120064107-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE PHOSPHO1, SGMS1, SGMS2 TSHR 2636/4885THPO 134/4885MAPT 2965/4885
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC TSHR 3583/4885THPO 837/4885MAPT 453/4885
US-20150005230-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC TSHR 3583/4885THPO 837/4885MAPT 453/4885
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC TSHR 3583/4885THPO 837/4885MAPT 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.